Published in N Engl J Med on July 23, 2008
Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11
Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet (2010) 9.53
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Human metabolic individuality in biomedical and pharmaceutical research. Nature (2011) 6.56
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J (2013) 4.87
Bayesian statistical methods for genetic association studies. Nat Rev Genet (2009) 4.37
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet (2010) 4.23
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet (2009) 3.83
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther (2012) 3.16
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum (2011) 2.99
Impact of OATP transporters on pharmacokinetics. Br J Pharmacol (2009) 2.97
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther (2011) 2.93
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension (2012) 2.86
Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs (2008) 2.62
Quality control procedures for genome-wide association studies. Curr Protoc Hum Genet (2011) 2.48
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature (2013) 2.46
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med (2011) 2.43
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest (2012) 2.33
Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther (2010) 2.22
Genome-wide association studies in pharmacogenomics. Nat Rev Genet (2010) 2.14
Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet (2009) 1.96
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92
Personalized medicine: hope or hype? Eur Heart J (2012) 1.80
The neurobiology of individual differences in complex behavioral traits. Annu Rev Neurosci (2009) 1.79
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov (2013) 1.78
Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J (2012) 1.75
Personalizing medicine with clinical pharmacogenetics. Genet Med (2011) 1.73
Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol (2014) 1.65
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics (2013) 1.65
SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther (2013) 1.61
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics (2010) 1.57
Treatment Options for Statin-Associated Muscle Symptoms. Dtsch Arztebl Int (2015) 1.55
Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy (2010) 1.55
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc (2015) 1.51
Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation (2011) 1.51
Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem (2009) 1.50
Personalized medicine using DNA biomarkers: a review. Hum Genet (2012) 1.49
Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet (2008) 1.48
A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet (2011) 1.48
Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med (2013) 1.48
Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One (2009) 1.43
What do drug transporters really do? Nat Rev Drug Discov (2014) 1.41
Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum Mol Genet (2008) 1.41
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information. PLoS Genet (2012) 1.41
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry (2010) 1.39
Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin (2009) 1.39
Genetic variation in metabolic phenotypes: study designs and applications. Nat Rev Genet (2012) 1.38
Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med (2016) 1.38
Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci (2011) 1.37
Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics (2011) 1.34
A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab (2013) 1.33
Biobanks and electronic medical records: enabling cost-effective research. Sci Transl Med (2014) 1.32
Strategic approaches to unraveling genetic causes of cardiovascular diseases. Circ Res (2011) 1.31
Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One (2011) 1.31
Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics (2013) 1.30
Genetic architecture of type 2 diabetes: recent progress and clinical implications. Diabetes Care (2009) 1.29
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun (2014) 1.28
Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.27
Age-related macular degeneration: genetic and environmental factors of disease. Mol Interv (2010) 1.24
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics (2011) 1.24
Non-cardiovascular effects associated with statins. BMJ (2014) 1.24
A genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid hormone regulation. PLoS Genet (2012) 1.23
Genetic background of patients from a university medical center in Manhattan: implications for personalized medicine. PLoS One (2011) 1.21
A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Prev Cardiol (2010) 1.21
Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos (2013) 1.18
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem (2012) 1.18
Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood (2012) 1.17
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther (2014) 1.17
Data-driven methods to discover molecular determinants of serious adverse drug events. Clin Pharmacol Ther (2009) 1.17
The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era. Hum Genet (2012) 1.16
Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle. Cell Metab (2014) 1.15
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics (2009) 1.15
Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink. Br J Clin Pharmacol (2014) 1.14
Genetic susceptibility to ischemic stroke. Nat Rev Neurol (2011) 1.12
The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med (2013) 1.12
Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. Prev Cardiol (2009) 1.11
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med (2013) 1.11
Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther (2014) 1.10
Pharmacogenomics: the genetics of variable drug responses. Circulation (2011) 1.10
Pharmacogenomics in clinical practice and drug development. Nat Biotechnol (2012) 1.08
Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics (2009) 1.08
The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. Br J Clin Pharmacol (2012) 1.07
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol (2011) 1.07
Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation (2011) 1.07
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther (2010) 1.06
Whole genome association studies in complex diseases: where do we stand? Dialogues Clin Neurosci (2010) 1.06
Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin. CPT Pharmacometrics Syst Pharmacol (2014) 1.05
Drug-related myopathies of which the clinician should be aware. Curr Rheumatol Rep (2010) 1.05
The impact of pharmacogenomics on the management of cardiac disease. Clin Pharmacol Ther (2011) 1.05
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature (1996) 27.61
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
The 1993-94 Généthon human genetic linkage map. Nat Genet (1994) 17.64
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29
A second-generation linkage map of the human genome. Nature (1992) 16.32
Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome. Genomics (1990) 13.23
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA (1998) 7.67
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
Chronic infections and coronary heart disease: is there a link? Lancet (1997) 7.18
Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol (1999) 6.42
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.86
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature (1993) 5.73
Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.50
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ (1991) 5.45
Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter. Nature (1986) 5.28
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet (2011) 5.08
Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA (1997) 4.09
Cellubrevin is a ubiquitous tetanus-toxin substrate homologous to a putative synaptic vesicle fusion protein. Nature (1993) 4.09
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet (2001) 3.71
Localization of the genetic defect in familial adenomatous polyposis within a small region of chromosome 5. Am J Hum Genet (1988) 3.58
A mapped set of DNA markers for human chromosome 17. Genomics (1988) 3.55
The rel-associated pp40 protein prevents DNA binding of Rel and NF-kappa B: relationship with I kappa B beta and regulation by phosphorylation. Genes Dev (1991) 3.52
Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol (1995) 3.51
Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ (1997) 3.51
Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet (2001) 3.50
Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet (1999) 3.17
Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation (2000) 3.05
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia (2013) 2.85
Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet (1988) 2.84
Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ (1991) 2.81
HC-Pro suppression of transgene silencing eliminates the small RNAs but not transgene methylation or the mobile signal. Plant Cell (2001) 2.74
Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet (2001) 2.72
A calmodulin-related protein that suppresses posttranscriptional gene silencing in plants. Science (2000) 2.65
Clathrin-coated vesicles in nervous tissue are involved primarily in synaptic vesicle recycling. J Cell Biol (1992) 2.59
Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem (1994) 2.59
Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nat Genet (1993) 2.56
Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet (1998) 2.53
Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology (2009) 2.46
Lessons learned in pediatric heart transplantation. Ann Thorac Surg (1989) 2.46
A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. N Engl J Med (1998) 2.42
Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med (2000) 2.31
Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J (2000) 2.30
A novel family of variable region genes of the human immunoglobulin heavy chain. J Mol Biol (1987) 2.27
Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) (1985) 2.27
Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry (2013) 2.25
The IMAGEN study: reinforcement-related behaviour in normal brain function and psychopathology. Mol Psychiatry (2010) 2.23
Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study. BMJ (1999) 2.18
Organization and evolution of variable region genes of the human immunoglobulin heavy chain. J Mol Biol (1986) 2.17
Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med (2003) 2.17
A detailed genetic map of the long arm of chromosome 11. Genomics (1990) 2.11
The prevalence of dental fear and avoidance: a recent survey study. J Am Dent Assoc (1983) 2.10
Chromosomal mapping of genetic loci associated with non-insulin dependent diabetes in the GK rat. Nat Genet (1996) 2.09
Large-scale randomized evidence: large, simple trials and overviews of trials. Ann N Y Acad Sci (1993) 2.08
Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med (1985) 2.04
Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue. Nucleic Acids Res (1986) 2.04
The effect of do-not-resuscitate orders on length of stay. Cleve Clin J Med (1992) 2.03
HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet (1992) 2.03
Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J Biol Chem (1994) 2.00
Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monogr Eval Carcinog Risk Chem Hum Suppl (1980) 1.99
Genetic influences on the end-stage effector phase of arthritis. J Exp Med (2001) 1.99
Robustness and power of the unified model in the analysis of quantitative measurements. Am J Hum Genet (1986) 1.98
Impact of early feeding on childhood eczema: development after nutritional intervention compared with the natural course - the GINIplus study up to the age of 6 years. Clin Exp Allergy (2010) 1.90
Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet (2002) 1.84
Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother (1981) 1.82
The Onchocerciasis Elimination Program for the Americas: a history of partnership. Rev Panam Salud Publica (1998) 1.79
The use of synthetic tandem repeats to isolate new VNTR loci: cloning of a human hypermutable sequence. Genomics (1991) 1.76
Genome screen for asthma and related phenotypes in the French EGEA study. Am J Respir Crit Care Med (2000) 1.75
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res (1981) 1.72
Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess (2005) 1.71
Linkage, physical mapping, and DNA sequence analysis of pseudoautosomal loci on the human X and Y chromosomes. Genomics (1987) 1.70
Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. N Engl J Med (1985) 1.68
Ataxia-telangiectasia: linkage analysis in highly inbred Arab and Druze families and differentiation from an ataxia-microcephaly-cataract syndrome. Hum Genet (1992) 1.68
Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol (1998) 1.59